13G Filing: Viking Global and Deciphera Pharmaceuticals LLC (DCPH)

Schedule 13G PAGE 15 of 16

CUSIP No. 24344T101

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief,
the undersigned certify that the information set forth in this statement is
true, complete and correct.

DATED: October 11, 2017

/s/ O. ANDREAS HALVORSEN
By: O. Andreas Halvorsen – individually and
as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP for itself and DRAGSA 14 LLC,
and as an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC,
VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP and
VIKING GLOBAL OPPORTUNITIES INTERMEDIATE LP

/s/ DAVID C. OTT
By: David C. Ott – individually and
as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP for itself and DRAGSA 14 LLC,
and as an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC,
VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP and
VIKING GLOBAL OPPORTUNITIES INTERMEDIATE LP

/s/ ROSE S. SHABET
By: Rose S. Shabet – individually and
as an Executive Committee Member of
Viking Global Partners LLC, on behalf of
VIKING GLOBAL INVESTORS LP for itself and DRAGSA 14 LLC,
and as an Executive Committee Member of
VIKING GLOBAL OPPORTUNITIES GP LLC, on behalf
of itself and VIKING GLOBAL OPPORTUNITIES PORTFOLIO GP LLC,
VIKING GLOBAL OPPORTUNITIES LIQUID PORTFOLIO SUB-MASTER LP and
VIKING GLOBAL OPPORTUNITIES INTERMEDIATE LP